



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

App. No. : 09/465,133
Applicant : Elisabetta Vegeto, et al
Filed : 12/15/1999
TC/AU : 1636
Examiner : Celine X. Qian

Confirmation No. 8491

Docket No. : 213-0041US
Customer No. : 25746

Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450


SECOND SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Dear Sirs and Mesdames:

Applicant desires to bring to the attention of the Examiner the following references listed on the attached Information Disclosure Statement, Form PTO 1449. A copy of each of the references is enclosed in compliance with 37 CFR § 1.97 and 1.98. Submission of this Information Disclosure Statement should not be construed as a representation that a search has been made or that no other material information as defined in 37 C.F.R. 1.56(a) exists. This submission is not intended to constitute an admission that any patent, publication or other information referred to herein is "prior art" to the invention disclosed unless specifically so designated. The right is reserved to antedate any item under 37 C.F.R. 1.131.


Authorization to charge Deposit Account No. 50-1922 is provided herewith for consideration of certain of these materials in accordance with 37 C.F.R. 1.17 (p) for submission of an Information Disclosure Statement under 37 C.F.R. 1.97(c). Should additional fees be required for the consideration of this IDS please consider this a request for consideration under the appropriate rule and an authorization for the Commissioner to charge and/ or credit should any additional fees be required or overpayment made.


Respectfully submitted,


Marilyn M. Huston, Reg. No. 37,851
WONG CABELLO LUTSCH RUTHERFORD & BRUCCULERI, LLP
20333 SH 249, Suite 600
Houston, Texas 77070
Direct (832) 446-2421, Facsimile (832) 446-2424

CERTIFICATE OF MAILING

I hereby certify that this document is being deposited with the U.S. Postal Service First Class Mail Service in an envelope addressed to Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450 on March 11, 2004.


Marilyn M. Huston



(Use as many sheets as necessary)

Sheet	1	of	6
-------	---	----	---

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Complete if Known

Application Number	09/465,133
Filing Date	December 15, 1999
First Named Inventor	Elisabetta Vegeto, et al.
Art Unit	1636
Examiner Name	Celine X. Qian
Attorney Docket Number	213-0041US

U. S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	1 ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)	MM-DD-YYYY			
	✓	WO 90/06318 A1.	06-14-1990	Evans, et al.		
	✓	WO 92/10591 A1	06-25-1992	Capon, et al.		
	✓	EP 0325849 B1	12-02-1988	Evans, et al.		
	✓	EP 0371820 B1	11-30-1989	Evans, et al.		
	✓	EP 0441483 A2	01-15-1991	McDonnell, et al.		
	✓	EP 0577932 A2	04-07-1993	Mak, et al.		


**Examiner
Signature**

Date
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



PTO/SB/08B (08-03)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet

2

of

6

Complete if Known

Application Number	09/465,133
Filing Date	December 15, 1999
First Named Inventor	Elisabetta Vegeto, et al.
Art Unit	1636
Examiner Name	Celine X. Qian
Attorney Docket Number	213-0041US

NON PATENT LITERATURE DOCUMENTS


Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		BAGCHI, M., Progesterone Enhances Target Gene Transcription by Receptor Free of Heat Shock Proteins hsp90, hsp56, and hsp70, Molecular and Cellular Biology, October 1991, pp. 4998-5004, Vol. 11, No. 10.	
	✓	BAGCHI, M., Steroid Hormone-Dependent Interaction of Human Progesterone Receptor with its Target Enhancer Element, Molecular Endocrinology, 1988, pp. 1221-1229, Vol. 2, No. 12.	
	✓	BAGCHI, M., Identification of a Functional Intermediate in Receptor Activation in Progesterone-Dependent Cell-Free Transcription, Nature, June 1990, pp. 547-550, Vol. 345.	
	✓	BAGCHI, M., Ligand and DNA-dependent Phosphorylation of Human Progesterone Receptor In Vitro, Proc. Natl. Acad. Sci. USA, April 1992, pp. 2664-2668, Vol. 89.	
	✓	BAULIEU, E., Contragestion and Other Clinical Applications of RU 486, an Antiprogesterone at the Receptor, Science, September 1989, pp. 1351-1357, Vol. 245.	
	✓	BAULIEU, E., Steroid Hormone Antagonists at the Receptor Level: A Role for the Heat-Shock Protein MW 90,000 (hsp 90), Journal of Cellular Biochemistry, 1987, pp. 161-174, Vol. 35.	
	✓	BENFREY, P., Regulated Genes in Transgenic Plants, Science, April 1989, pp. 174-181, Vol. 244.	
	✓	BENHAMOU, B., A Single Amino Acid That Determines the Sensitivity of Progesterone Receptors to RU486, Science, January 1992, pp. 206-209, Vol. 255.	
	✓	BOCQUEL, M., The Contribution of the N-and C-Terminal Regions of Steroid Receptors to Activation of Transcription is Both Receptor and Cell-Specific, Nucleic Acids Research, 1989, pp. 2581-2595, Vol. 17.	
	✓	BROWN, D., Gene Therapy 'Oversold' By Researchers, The Washington Post, Friday, December 8, 1995, pp. A1/A22.	

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



PTO/SB/08B (08-03)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Applicant Number	09/465,133
Filing Date	December 15, 1999
First Named Inventor	Elisabetta Vegeto, et al.
Art Unit	1636
Examiner Name	Celine X. Qian
Attorney Docket Number	213-0041US

Sheet	3	of	6
-------	---	----	---

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	✓	BURNSTEIN, K., Intragenic Sequences of the Human Glucocorticoid Receptor Complementary DNA Mediate Hormone-Inducible Receptor Messenger RNA Down-Regulation through Multiple Mechanisms, Molecular Endocrinology, 1994, pp. 1764-1773, Vol. 8, No. 12.	
	✓	BYRAVAN, S., Two Point Mutations in the Hormone-Binding Domain of the Mouse Glucocorticoid Receptor That Dramatically Reduce Its Function, Molecular Endocrinology, 1991, pp. 752-758, Vol. 5, No. 6.	
	✓	CARSON, M., Structure-Function Properties of the Chicken Progesterone Receptor A Synthesized from Complementary Deoxyribonucleic Acid, Molecular Endocrinology, 1987, pp. 791-801, Vol. 1, No. 11.	
	✓	CARSON-JURICA, M., Steroid Receptor Family: Structure and Functions, Endocrine Reviews, 1990, pp. 201-220, Vol. 11, No. 2.	
	✓	CATO, A.C.B., The Hormone Regulatory Element of Mouse Mammary Tumour Virus Mediates Progesterone Induction, The EMBO Journal, 1986, pp. 2237-2240, Vol. 5, No. 9.	
	✓	CHAO, C.C., Ionic and Ligand-Specific Effects on the DNA Binding of Progesterone Receptor Bound to the Synthetic Progestin R5020 and the Antiprogestin RU486, Cancer Research, 1991, pp. 3938-2945, Vol. 51.	
	✓	CHEN, D., The Hormone-Binding Role of 2 Cysteines Near the C Terminus of The Mouse Glucocorticoid Receptor, The Journal of Biological Chemistry, 1994, pp. 7914-7918, Vol. 269.	
	✓	CHRISTENSEN, K., Characterization and Functional Properties of the A and B Forms of Human Progesterone Receptors Synthesized in a Baculovirus System, Molecular Endocrinology, 1991, pp. 1755-1770, Vol. 5, No. 11.	
	✓	CHRISTOPHERSON, K., Ecdysteroid-Dependent Regulation of Genes in Mammalian Cells by a Drosophila Ecdysone Receptor and Chimeric Transactivators, Proc. Natl. Acad. Sci. USA, July 1992, pp. 6314-6318, Vol. 89.	
	✓	COGHLAN, A., Gene Dream Fades Away, New Scientist, November 1995, pp. 14-15.	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



PTO/SB/08B (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Application Number	09/465,133
Filing Date	December 15, 1999
First Named Inventor	Elisabetta Vegeto, et al.
Art Unit	1636
Examiner Name	Celine X. Qian
Attorney Docket Number	213-0041US

Sheet 4 of 6

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	✓	CONNELLY, O., The A and B Forms of the Chicken Progesterone Receptor Arise by Alternate Initiation of Translation of a Unique mRNA, Biochemical and Biophysical Research Communications, 1987, pp. 493-501, Vol. 149, No. 2.	
	✓	CONNELLY, O., The Chicken Progesterone Receptor A and B Isoforms Are Products of an Alternate Translation Initiation Event, The Journal of Biological Chemistry, 1989, pp. 14062-14064, Vol. 264, No. 24.	
	✓	DENNER, L., Regulation of Progesterone Receptor-Mediated Transcription by Phosphorylation, Science, 1990, pp. 1740-1743, Vol. 250.	
	✓	EL-ASHRY, D., Human Progesterone Receptor Complexed with the Antagonist RU 486 Binds to Hormone Response Elements in a Structurally Altered Form, Molecular Endocrinology, 1989, pp. 1545-1558, Vol. 3, No. 10.	
	✓	ELLISTON, J., Hormone Activation of Baculovirus Expressed Progesterone Receptors, The Journal of Biological Chemistry, 1992, pp. 5193-5198, Vol. 267, No. 8.	
	✓	Evans, R.M., "The Superfamily of Ligand-Responsive Transcription Factors", Published Proceedings of the Tenth Annual University of California, Riverside-Nichols Institute Symposium on Cellular and Molecular Endocrinology, 1988, pp. 132-142.	
	✓	FAWELL, S., Characterization and Colocalization of Steroid Binding and Dimerization Activities in the Mouse Estrogen Receptor, Cell, 1990, pp. 953-962, Vol. 60.	
	✓	FREEDMAN, L., On the Mechanism of DNA Binding by Nuclear Hormone Receptors: A Structural and Functional Perspective, Journal of Cellular Biochemistry, 1993, pp. 140-150, Vol. 51.	
	✓	GIGUERE, V., Functional Domains of the Human Glucocorticoid Receptor, Cell, 1986, pp. 645-652, Vol. 46.	
	✓	GROYER, A., Antigluccorticosteroid Effects Suggest Why Steroid Hormone is Required for Receptors to Bind DNA In Vivo but not In Vitro, Nature, 1987, pp. 624-626, Vol. 328.	


Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



PTO/SB/08B (08-03)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Application Number	09/465,133
Filing Date	December 15, 1999
First Named Inventor	Elisabetta Vegeto, et al.
Art Unit	1636
Examiner Name	Celine X. Qian
Attorney Docket Number	213-0041US

Sheet	5	of	6
-------	---	----	---

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	✓	GUIOCHON-MANTEL, A., Receptors Bound to Antiprogesterin Form Abortive Complexes With Hormone Responsive Elements, Nature, 1998, pp. 695-698, Vol. 336.	
	✓	KLEIN-HITPASS, L., The Progesterone Receptor Stimulates Cell-Free Transcription by Enhancing the Formation of a Stable Preinitiation Complex, Cell, 1990, pp. 247-257, Vol. 60.	
	✓	HOUDEBINE, L., Production of Pharmaceutical Proteins from Transgenic Animals, Journal of Biotechnology, 1994, pp. 269-287, Vol. 34.	
	✓	HORWITZ, K., The Antiprogesterin RU38 486: Receptor-Mediated Progesterin Versus Antiprogesterin Actions Screened in Estrogen-Insensitive T47Dco Human Breast Cancer Cells, Endocrinology, 1985, pp. 2236-2244, Vol. 116, No. 6.	
	✓	LANZ, R., Trans-Dominant Negative Glucocorticoid Receptor Mutants, Journal of Cellular Biochemistry, 1993, supplement 17A, pp. B650.	
	✓	MCDONNELL, D., Functional Domains of the Human Vitamin D3 Receptor Regulate Osteocalcin Gene Expression, Molecular Endocrinology, 1989, pp. 635-644, Vol. 3, No. 4.	
		MCDONNELL, D., Reconstitution of the Vitamin D-Responsive Osteocalcin Transcription Unit in Saccharomyces cerevisiae, Molecular and Cellular Biology, 1989, pp. 3517-3523, Vol. 9, No. 8.	
	✓	MULLIGAN, R., The Basic Science of Gene Therapy, Science, 1993, pp. 926-932, Vol. 260.	
	✓	PRIVALSKY, M., The Viral erbA Oncogene Protein, a Constitutive Repressor in Animal Cells, Is a Hormone-Regulated Activator in Yeast, Cell, 1990, pp. 1277-1286, Vol. 63.	
	✓	PTASHNE, M., How Eukaryotic Transcriptional Activators Work, Nature, 1988, pp. 683-689, Vol. 335.	


Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



PTO/SB/08B (08-03)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Application Number 09/465,133

Filing Date December 15, 1999

First Named Inventor Elisabetta Vegeto, et al.

Art Unit 1636

Examiner Name Celine X. Qian

Attorney Docket Number 213-0041US

Sheet 6

of 6

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	✓	SHEMSHEDINI, L., In Vitro Activity of the Transcription Activation Functions of the Progesterone Receptor, The Journal of Biological Chemistry, January 1992, pp. 1834-1839, Vol. 267, No. 3.	
	✓	STRASSER-WOZAK, E., Splice Site Mutation in the Glucocorticoid Receptor Gene Causes Resistance to Glucocorticoid-Induced Apoptosis in a Human Acute Leukemic Cell Line, Cancer Research, 1995, pp. 348-353, Vol. 55.	
	✓	TAKIMOTO, G., Hormone-Induced Progesterone Receptor Phosphorylation Consists of Sequential DNA-Independent and DNA-Dependent Stages: Analysis with Zinc Finger Mutants and the Progesterone Antagonist ZK98299, Proc. Natl. Acad. Sci. USA, 1992, pp. 3050-3054, Vol. 89.	
	✓	VAN BRUNT, J., Molecular Farming: Transgenic Animals as Bioreactors, Biotechnology Nature Publishing, 1988, pp. 1149-1154, Vol. 6, No. 10	
	✓	WANG, C, pH-Sensitive Immunoliposomes Mediate Target-Cell-Specific Delivery and Controlled Expression of a Foreign Gene in Mouse, Proc. Natl. Acad. Sci. USA, 1987, pp. 7851-7855, Vol. 84.	
	✓	WANG, Y., A Regulatory System for Use in Gene Transfer, Proc. Natl. Acad. Sci. USA, 1994, pp. 8180-8184, Vol. 91.	
	✓	WOLFF, J., Grafting Fibroblasts Genetically Modified to Produce L-Dopa in a Rat Model of Parkinson Disease, Proc. Natl. Acad. Sci. USA, 1989, pp. 9011-9014, Vol. 86.	
	✓	WOOGE, CH, Structural Requirements for High Affinity Ligand Binding by Estrogen Receptors: A Comparative Analysis of Truncated and Full Length Estrogen Receptors Expressed in Bacteria, Yeast, and Mammalian Cells, Molecular Endocrinology, 1992, pp. 861-869, Vol. 6, No. 6.	

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.